Advice
Following a full submission.
Accepted for restricted use within NHS Scotland
Mometasone is the fourth inhaled steroid licensed for treatment of asthma. It is available as a dry powder inhaler. It has a similar efficacy and adverse event profile to other currently available inhaled steroids. It is suitable for use as a second line agent following treatment failure on first line inhaled steroids.
Download detailed advice18KB (PDF)
Medicine details
- Medicine name:
- Mometasone furoate (Asmanex Twisthaler®)
- SMC ID:
- 79/03
- Indication:
- Asthma
- Pharmaceutical company
- Schering-Plough Ltd
- BNF chapter
- Respiratory system
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 10 November 2003